A detailed history of California State Teachers Retirement System transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, California State Teachers Retirement System holds 55,061 shares of DAWN stock, worth $672,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,061
Previous 47,381 16.21%
Holding current value
$672,294
Previous $652,000 17.48%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.72 - $16.03 $97,689 - $123,110
7,680 Added 16.21%
55,061 $766,000
Q2 2024

Aug 14, 2024

SELL
$12.03 - $17.69 $23,566 - $34,654
-1,959 Reduced 3.97%
47,381 $652,000
Q1 2024

May 15, 2024

SELL
$13.56 - $17.46 $48,585 - $62,559
-3,583 Reduced 6.77%
49,340 $815,000
Q4 2023

Feb 13, 2024

BUY
$9.68 - $15.37 $7,076 - $11,235
731 Added 1.4%
52,923 $772,000
Q3 2023

Nov 14, 2023

SELL
$11.22 - $14.86 $102,315 - $135,508
-9,119 Reduced 14.87%
52,192 $640,000
Q2 2023

Aug 21, 2023

BUY
$11.74 - $14.47 $598,939 - $738,215
51,017 Added 495.6%
61,311 $732,000
Q1 2023

May 09, 2023

SELL
$12.75 - $23.41 $9,690 - $17,791
-760 Reduced 6.88%
10,294 $137,000
Q4 2022

Feb 14, 2023

BUY
$18.77 - $22.0 $2,346 - $2,750
125 Added 1.14%
11,054 $237,000
Q3 2022

Nov 18, 2022

BUY
$16.44 - $26.57 $15,519 - $25,082
944 Added 9.45%
10,929 $219,000
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $1,704 - $5,334
298 Added 3.08%
9,985 $179,000
Q1 2022

May 16, 2022

BUY
$9.12 - $17.47 $32,658 - $62,560
3,581 Added 58.65%
9,687 $96,000
Q4 2021

Feb 15, 2022

BUY
$15.65 - $26.33 $2,331 - $3,923
149 Added 2.5%
6,106 $103,000
Q3 2021

Nov 15, 2021

BUY
$20.0 - $27.92 $119,140 - $166,319
5,957 New
5,957 $141,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $897M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.